SUPPLEMENTARY TEXT: DESCRIPTION OF THE ...europepmc.org/articles/PMC2846760/bin/NIHMS180501... ·...

DETAILED DISCUSSION OF CANDIDATE GENES IN SEVEN NEW LOCI(see also Figure 1)

rs1465618 on chromosome 2p21 is in intron 30 of THADA, a gene disrupted by

rearrangement in thyroid adenomas and part of the death receptor pathway1, 2. Another

SNP, rs7578597 is in exon 24 of THADA and has been associated with type 2 diabetes3.

Alleles in TCF2 and JAZF1 have also been shown to be susceptibility loci for both

diabetes and PrCa. This locus may provide another example of this phenomenon.

rs12621278 on 2q31 is in intron 1 of ITGA6, the gene encoding integrin alpha 6. Integrins

control cell attachment to the extracellular matrix and mediate cell proliferation, migration

and survival. ITGA6 may also be considered as a potential therapeutic target, as its up-

regulation is associated with a metastatic phenotype and an increase in cancer cell

motility, including for PrCa4. rs12500426 and rs17021918 on 4q22 are in introns 7 and 9,

respectively, of PDLIM55. LIM domain-containing proteins are scaffolds involved in

cytoskeleton organization, cell lineage specification, organ development, and

oncogenesis. rs7679673 on 4q24 lies 90kb upstream of TET2, coding for a DNA binding

zinc finger protein. TET2 is widely expressed, with highest expression levels found in

prostate and bone marrow, and mutations of TET2 have been reported in myelodysplasia

cases6. rs2928679 and rs1512268 are 90kb apart on 8p21. Thus, they may be markers for

the same causal variant, but given that they are in separate LD blocks, they could also

indicate the presence of two distinct causal alleles. An interesting candidate gene in this

general region is NKX3.1 (rs1512268 is 10kb downstream of NKX3.1), which codes for the

androgen-regulated homeobox protein NKX3.1. This is important for maintenance of

normal prostate tissue and is expressed at all stages of prostate development and in adult

prostate7. Loss of heterozygosity at 8p21 is frequently observed in early PrCa. NKX3.1 is

up-regulated by androgens and simultaneous loss of NKX3.1 and PTEN is common in

PrCa initiation8. NKX3.1 stabilises TP53 via Akt independent mechanisms8; it associates

with HDAC1, preventing deacetylation and destabilisation of TP53 by HDAC1/MDM2,

thereby promoting apoptosis. Of note, HDAC inhibitors have been developed as targeted

therapies and are currently in trial in metastatic PrCa9. NKX3.1 also downregulates

expression of PSA by PDEF10 (an epithelium-specific Ets transcription factor, which plays

a role in PrCa), therefore loss of NKX3.1 results in increased PSA expression. rs7127900

is in a region on 11p15 that includes several plausible candidate genes: IGF2, IGF2AS,

INS and TH. The first three are members of the insulin family of polypeptide growth

factors11. A SNP in H19, a regulator of IGF2 that lies telomeric to this region, has been

associated with breast cancer risk12. rs5759167 lies on chromosome 22q13, for which

evidence of linkage to PrCa has been found13,14, 15. This SNP is ~7Mb downstream from

the previously reported linkage peak. There are several genes of interest in the LD block

(see figure 1).

SUPPLEMENTARY TEXT: DESCRIPTION OF THE PRACTICAL CONSORTIUM GROUPS

Subjects were included from 21 studies comprising PrCa cases and controls: eight

from Europe, nine from North America, one from China, and three from Australia.

These comprised 16, 332 PrCa cases and 16, 344 male controls. Details are shown

in supplementary Table 4. Some have previously been described as part of work in

the PRACTICAL Consortium16. The Mayo Clinic and Utah studies oversampled cases

from multiple case families and only one case per family was genotyped. Three of the

studies contained men of Asian ancestry (China and Japan); six of the studies

contained men of African American ancestry and two studies contained men of

Latino (Hispanic) origin; one study was from Hawaii (see Figure 2). The remaining

studies were predominantly of men of European ancestry. All studies have the

relevant IRB approval in each country in accordance with the principles embodied in

the Declaration of Helsinki. Details of each study set are given below, and a

summary of the studies is given in Supplementary Table 4.

BiPAS: The Birmingham Prostatic Neoplasms Association Study (BiPAS) – A Genetic and Environmental Case Control StudyThe Birmingham Prostatic Neoplasms Association Study base consists of men living

in the south Birmingham area, United Kingdom aged >50 years. The study recruited

men with lower urinary tract symptoms (LUTS) and/or high serum prostate specific

antigen (PSA) levels referred for prostate biopsies between March 2007 until October

2008. PrCa cases were recruited from the Queen Elizabeth Medical Centre,

Birmingham. Cases are defined as men with histologically confirmed

adenocarcinoma of the prostate. Controls were also recruited from the Queen

Elizabeth Medical Centre and Selly Oak Hospital, Birmingham. Men with a normal

repeat PSA and a negative biopsy were categorized as benign controls.

A blood sample from every hospital based subject was obtained using standard

venepuncture methods, and collected in a 5ml tube containing EDTA. Samples were

transported to the laboratory immediately in a cool bag with cool packs and stored at

4°C. DNA was extracted using the QIAGEN maxi blood kit.

CHSH: ChinaAll samples were from men of Chinese Han origin from Shanghai and its surrounding

city. Patients with PrCa enrolled in the study were diagnosed by transrectal

ultrasonographic prostate biopsy, and confirmation of the pathologic diagnoses for

those who underwent radical prostatectomy. They were from two hospitals; Changhai

hospital and Changzheng Hospital in Shanghai, China.

Controls are hospital based and are from other clinical divisions which are treating

non cancer patients; these have a PSA level of < 3.0ng/ml, and are age matched (+/-

3 years).

FHCRC: Fred Hutchinson Cancer Research Center, Seattle USAThe study population consists of participants from two population-based case-control

studies in Caucasian and African American residents of King County, Washington

(Study I and Study II), which have been previously described. Incident cases with

histologically confirmed PrCa were ascertained from the Seattle-Puget Sound

Surveillance, Epidemiology and End Results cancer registry. In Study I, cases were

diagnosed between January 1, 1993, and December 31, 1996 and were 40-64 years

of age at diagnosis. In Study II, cases were diagnosed between January 1, 2002,

and December 31, 2005 and were 35-74 years of age at diagnosis. Overall, 2,244

eligible PrCa patients were identified and 1,754 (78%) were interviewed. Blood

samples yielding sufficient DNA for genotyping were drawn from 1,457 (83%) cases

who completed the study interview.

A comparison group of controls without a history of PrCa, residing in King County,

Washington, was identified for each study using random digit telephone dialing.

Controls were frequency-matched to cases by five-year age groups and recruited

evenly throughout each ascertainment period for cases. A total of 2,448 men were

identified who met the eligibility criteria and 1,645 (67%) completed a study interview.

Blood samples were drawn and DNA prepared from 1,352 (82%) interviewed

controls.

FMHS: Michigan, USThe Flint Men’s Health Study (FMHS) is a community-based, case-control study of

PrCa in African American men living in Genesee County, MI, US conducted from

1996 to 2002. Controls were recruited from a probability sample of African American

men aged 40-79 years with intentional over-sampling from older age groups. Cases

were identified from the Genesee County Community-Wide Hospital Oncology

Program registry. Participants provided blood samples from which DNA and serum

were isolated and completed detailed interviews which addressed potential risk

factors for PrCa, urinary symptoms, PrCa screening history and general medical

history, socio-economic factors, and access to and use of health care. Additionally,

controls underwent urological examinations and PSA screening and cases provided

access to medical records pertaining to their PrCa diagnoses. A total of 383 controls

participated in all portions of the study. Nineteen of those controls were diagnosed

with PrCa during the time of the study and subsequently recruited as cases. DNA is

currently available for 356 of the remaining controls. A total of 136 cases participated

in all portions of the study and DNA is currently available for 133 cases.

HaPCS: Hannover, GermanyA hospital-based series of 499 unselected Caucasian patients with PrCa who were

treated with brachytherapy between October 2000 and September 2007 at Hannover

Medical School, were enrolled for this study17. All patients had biopsy-proven

adenocarcinoma of the prostate. Indication for permanent brachytherapy was

clinically localized low risk early PrCa (cT2a or less with a PSA serum level < 10

ng/ml and a Gleason score < 7) following the European Society for Therapeutic

Radiology and Oncology/European Assocation of Urology/European Organization for

Research and Treatment of Cancer recommendations. The median age at diagnosis

was 67 years in this patient series (range 42-82 years). For comparison, a series of

504 genomic DNA samples was established from ethnically matched adult male

blood donors at Hannover Medical School in the period from 2006-2007.

MAYO: The MAYO clinic: Rochester, Minnesota, USAThe Mayo Clinic study consisted of hospital-based cases, including 476 affected men

from 185 families with PrCa, 445 men with sporadic PrCa, 199 with aggressive

(Gleason score > 7) PrCa, and 500 population-based controls. The controls (all

males) were randomly selected from a sampling frame of Olmsted County,

Minnesota, provided by the Rochester Epidemiology Project. The methods used to

ascertain familial and sporadic PrCa patients, as well as controls, have been

described previously18. All individuals from the Mayo Clinic study included in this

report were of self-reported European descent.

MCCS: Melbourne Collaborative Cohort Study, Melbourne, AustraliaMCCS/RFPCS/EOPCFS: Cancer Council Victoria, Melbourne, Australia The Melbourne Collaborative Cohort Study (MCCS) is a prospective cohort of 17,154

men aged 40 to 69 years at recruitment in 1990-4. MCCS participants were

diagnosed with PrCa during follow-up to mid 2006 and were ascertained through

linkage with the Victorian Cancer Registry and the National Cancer Statistics

Clearing House that includes diagnoses from other States in Australia. The Risk

Factors for Prostate Cancer Study (RFPCS) is a population based case-control study

that in the period 1994-1997 recruited through State Cancer Registries men resident

in Perth and Melbourne diagnosed with prostate cancer at age less than 70 years.

The Early-Onset Prostate Cancer Family Study (EOPCFS) is a population-based

study of prostate cancer in men diagnosed at age less than 56 years ascertained

through the Victorian Cancer Registry. Controls for stage 3 were a random sample of

the MCCS participants that were not diagnosed with PrCa during follow-up. All study

subjects were of Caucasian origin. Participants in the three studies whose samples

were used for stage 2 were excluded from stage 3.

MEC: The Multiethnic Cohort StudyThe Multiethnic Cohort Study19 is a population-based prospective cohort study that

was initiated between 1993 and 1996 and includes subjects from various ethnic

groups -African-Americans and Latinos primarily from California (mainly Los

Angeles) and Native Hawaiians, Japanese-Americans, and European Americans

primarily from Hawaii. State drivers’ license files were the primary sources used to

identify study subjects in Hawaii and California. Additionally, in Hawaii, state voter's

registration files were used, and, in California, Health Care Financing Administration

(HCFA) files were used to identify additional African American men. All participants

(n=215,251) returned a 26-page self-administered baseline questionnaire that

obtained general demographic, medical and risk factor information. In the cohort,

incident cancer cases are identified annually through cohort linkage to population-

based cancer Surveillance, Epidemiology, and End Results (SEER) registries in

Hawaii and Los Angeles County as well as to the California State cancer registry.

Information on stage and grade of disease are also obtained through the SEER

registries. Blood sample collection in the MEC began in 1994 and targeted incident

PrCa cases and a random sample of study participants to serve as controls for

genetic analyses. This nested PrCa case-control study in the MEC consists of 2,792

invasive PrCa cases and 2,377 controls. This study was approved by the Institutional

Review Boards at the University of Southern California and at the University of

Hawaii and informed consent was obtained from all study participants.

MOFFITT: Moffitt Study, Tampa, Florida, USThis is a hospital-based incident study of 646 patients with primary

adenocarcinoma of the prostate (560 whites, 55 African Americans, 28 white

Hispanics and 3 others). They were recruited from 2002 to 2007 at the H. Lee Moffitt

Cancer Center (Tampa, FL, US) and James A. Haley Veterans Affairs Hospital

(Tampa, FL, US). Ninety-five percent of the case subjects who were asked to

participate in the study agreed. All cancer cases were histologically confirmed by the

Department of Pathology at each institution.

The controls consisted of 320 subjects (302 whites, 10 African Americans, 6 white

Hispanics and 2 others) who were visiting the Lifetime Cancer Screening Center,

which is affiliated with the H. Lee Moffitt Cancer Center. At this center, routine

screenings are offered to men for cancers of the prostate, colorectum, and skin. Men

could have been self-referred or directed for screening by their primary healthcare

provider. All control subjects were male and had had no previous diagnosis of

cancer. The control subjects were frequency matched to the patients by age at

diagnosis (± 5 years). Eighty-three percent of the control subjects who were asked to

participate in the study consented.

Non-genetic risk factor data for the present study were obtained through in-person

interviews with the patients and controls at enrollment. The questionnaire covered

demographic information, family history of cancer (ie, whether they have one or more

first-degree family member with PrCa), medical history, and detailed tobacco

consumption. For the patients, data on cancer stage, Gleason score, and prostate

specific antigen level were abstracted from the medical records. The subjects were

asked to provide a blood or buccal sample after the interview as a source of genomic

DNA20.

NC_CCPC: San Francisco, California USA This population-based case-control study of advanced PrCa in non-Hispanic white

and African-American men was conducted in the San Francisco Bay Area. Newly

diagnosed cases aged 40-79 years were identified through the regional cancer

registry, which is part of the Surveillance, Epidemiology and End Results (SEER)

Cancer Registry Program. Non-Hispanic white cases were diagnosed between July,

1 1997 and February 28, 2000, and African-American cases were diagnosed

between July 1, 1997 and December 31, 2000. Overall, 1,015 patients with a first

primary advanced PrCa were identified. Of these, 106 were deceased at the time of

contact, 33 were enrolled in another study and thus not available, 12 were declined

contact by their physician, and 76 no longer lived in the San Francisco Bay area or

did not meet other eligibility criteria. Of 788 eligible cases contacted, 568 (72%)

completed the interview and 533 (68%) provided a biospecimen sample. DNA from

blood samples was available for 389 cases.

Non-Hispanic white and African-American population controls aged 40-79 years were

identified through random-digit dialing. In addition, controls aged 65-79 years were

randomly selected from the rosters of beneficiaries of the Health Care Financing

Administration (HCFA). Controls were frequency-matched to cases by five-year age

group and race. Of 1,081 controls selected into the study 16 were deceased at the

time of contact, 41 had a history of PrCa, and 156 did not meet other eligibility

criteria. Of 868 eligible controls contacted, 545 (63%) completed the interview and

525 (60%) provided a biospecimen sample. DNA from blood samples was available

for 256 controls [John et al., 2005].

PCMUS: BulgariaThe Bulgarian sample of PrCa patients consist mainly of newly diagnosed cases,

which are histopathologically confirmed. The patients (N=114, age range 51-91) are

of Bulgarian origin. Transrectal biopsy was performed at the Urology Clinic,

Alexandrovska University Hospital, mainly because of an elevated PSA. Some of the

patients were referred from other centers to the tertiary university hospital after being

previously diagnosed with PrCa. A small subset of patients had previously had

definitive treatment (mainly radical prostatectomy), and they were called

retrospectively for invitation to join the study. The control group is matched to the

patients by sex, age, and ethnicity. It consists of two groups: (i) 96 healthy males,

age range 51-86, presenting to our institution with lower urinary tract symptoms

caused by benign prostatic hypertrophy (BPH) who had a PSA <3.5. The majority of

them subsequently underwent surgical treatment with histological verification of the

BPH; (ii) an additional healthy control group of 110 anonymous males matched to the

PrCa patients by age and ethnicity, but with no PSA data.

All participants gave written informed consent and anonymous controls have been

selected from the available DNA bank at Molecular Medicine Center, Medical

University Sofia.

PENN, (SCORE), University of Pennsylvania, Philadelphia, USIncident PrCa cases were identified through Urologic Clinics between 1995 and

2008. Case status was confirmed by medical records review using a standardized

abstraction form. Cases were excluded from this study if they reported having

exposure to finasteride (Proscar) at the time of their PrCa diagnosis. Patients who

were non-incident cases (i.e., those diagnosed more than twelve months prior to the

date of study ascertainment), or had a prior diagnosis of cancer at any site except

non-melanoma skin cancer, were also excluded. Risk factor, medical history, PrCa screening history, and PrCa diagnostic information

was obtained by using a standardized questionnaire and review of medical records.

Information collected included personal history of benign prostatic hyperplasia (BPH)

and vasectomy, previous cancer diagnoses, and demographic information, and PrCa

screening history. Existence of BPH was confirmed by medical records review.

Genomic DNA for the present study was self-collected by each study participant

using sterile cheek swabs (Cyto-Pak Cytosoft Brush, Medical Packaging Corporation,

Camarillo, CA), and processed using either a protocol modified from Richards et al.

(1993)21 as described previously22 or using a modified protocol on the Qiagen 9604B

robot with the QIAamp 96 DNA Buccal Swab Biorobot Kit (Valencia, CA).

ProtecT, UK ProtecT [ Donovan et al, 2003] is a national study of community-based PSA testing

and a randomised trial of subsequent PrCa treatment. Approximately 200,000 men

between the ages of 50 and 69 years, ascertained through general practices in nine

regions in the UK, were approached and 100, 000 were recruited. Men known to be

non-white were excluded. For this study, 1800 cases identified by PSA screening

within the ProtecT study were analysed. Controls (1800) with normal PSA levels

(<3ng/ml) were selected from the same GP register and 5 year age band as the

cases.

QUEENSLAND: Australia The Queensland cases were ascertained from two studies: (i) a series of men

recruited through QUT/QIMR within two years of their diagnosis of prostate cancer

(Retrospective Queensland Study), and identified through physician referrals from

three hospitals in Brisbane, Queensland (N=176, age range 51-87 years) (ii) a

longitudinal cohort study (Prostate Cancer Supportive Care and Patient Outcomes

Project: ProsCan) being conducted through CCQ in Queensland, through which men

newly diagnosed with prostate cancer from 26 private practices and 8 public

hospitals were directly referred to ProsCan at the time of diagnosis by their treating

clinician (N=780, age range 43-88 years)23. All cases had histopathologically

confirmed prostate cancer, following presentation with an abnormal serum PSA

and/or lower urinary tract symptoms. Controls, recruited through QUT and QIMR,

comprised healthy male blood donors with no personal history of prostate cancer,

from the (i) the Australian Red Cross Blood Services in Brisbane (N=834, age range

19-76 years)24 and (ii) the Australian Electoral Commission (N=559, age and post-

code/ area matched to ProsCan, age range 54-90 years).

TAMPERE: Finland Samples (3543 total) were collected in Tampere and Helsinki and are all of Finnish

origin. The mean age of diagnosis for the 1485, unselected consecutive PrCa

patients from Tampere was 69 years (range 43-95). The patients were diagnosed

with PrCa in 1993-2008 in the Tampere University Hospital, Department of Urology.

Tampere University Hospital is a regional referral center in the area for all patients

with PrCa, which results in an unselected, population-based collection of patients.

The rest of the cases, 284 men, were diagnosed in 2004-2007 in the Finnish PSA-

screening Trial from the Hospital district of Helsinki and Uusimaa. Their mean age at

diagnosis was 66 years (range 62-74) For controls, two groups of samples were

used: (i)the 835 Finnish population controls consisted of DNA samples from

volunteer, anonymous, healthy male blood donors obtained from the Blood Center of

the Finnish Red Cross in Tampere, and (ii) the 938 men with a PSA of <1ng/ml were

selected from the PSA-screening trial.

TASPRAC: Tasmania, AustraliaThe thirty-one familial PrCa cases genotyped for this study were drawn from the

Tasmanian Familial Prostate Cancer Study, which has recruited families with multiple

individuals affected with PrCa. These families were identified using the records of the

Tasmanian Cancer Registry (a register of all cancer diagnoses in Tasmania,

Australia since 1978) and the genealogical records from the Menzies Research

Institute Genealogical Database; they comprise at least 2 affected first-degree

relatives. One case per family was selected for inclusion. Blood samples, pathology

specimens and pathology reports are available for these familial cases. The

remaining 492 sporadic PrCa cases were drawn from the Tasmanian Prostate

Cancer Case Control Study. Cases were again identified from the Tasmanian Cancer

Registry, and eligible cases were men <70 years diagnosed with histologically

confirmed PrCa diagnosed between 1996 and 2005. Controls were randomly

selected from the Tasmanian electoral roll (registration on the electoral roll is

compulsory in Australia for individuals > 18 years). Eligible controls were sex and

age-matched within 5-year age groups to the sporadic cases and self-reported as

unaffected with PrCa. Blood samples, physical measures, dietary history,

environmental exposure data and family history have been collected from

participating individuals. Of note, controls diagnosed with PrCa subsequent to their

recruitment have been removed from the control dataset. Notification of their

subsequent diagnosis with PrCa was determined by their registration as a confirmed

case by the Tasmanian Cancer Registry as of the end of 200725,26

UKGPCS, UK Samples were ascertained through the UKGPCS (UK Genetic Prostate Cancer

Study) and through a systematically collected series from PrCa clinics in the Urology

Unit at The Royal Marsden NHS Foundation Trust over a 14 year period.

Controls were collected as part of the “Gene-Environment Interactions in Prostate

Cancer” or The Prostate Cancer Research Foundation studies run from the

University of Nottingham from GP practices participating in the UKGPCS. They had

no personal or family history of PrCa.

ULM: Germany

Cases were recruited in two different ways. Familial PrCa probands (index cases)

were ascertained from all over Germany. They were advised by their attending

physicians to contact the Clinic of Urology of Ulm. The positive family history was

then verified by reviewing medical records or death certificates of family members. In

each case, only one member of each family (e.g. the proband) was enrolled in the

present study. Sporadic cases, who reported no relatives affected with PrCa, were

almost exclusively collected at Ulm during their course of treatment (e.g. radical

prostatectomy) in our Urology Clinic. The control group consists of 213 age-matched

healthy men and 295 population controls of unknown disease status.

USC: Los Angeles, Southern California, USASubjects were participants in a population-based case-control study of aggressive

PrCa conducted in Los Angeles County. Cases were identified through the Los

Angeles County Cancer Surveillance Program rapid case ascertainment system

Large hospitals are screened at least weekly and other sites at least monthly.

Eligible cases included African American, Hispanic, and non-Hispanic white men

diagnosed with a first primary PrCa between January 1, 1999 and December 31,

2003. Eligible cases also had either (1) prostatectomy with documented tumor

extension outside the prostate, (2) metastatic PrCa in sites other than prostate, (3)

needle biopsy of the prostate with Gleason grade >8 or (4) needle biopsy with

Gleason grade 7 and tumor in more than 2/3 of the biopsy cores.

Eligible controls were men never diagnosed with PrCa, living in the same

neighborhood as a case, and were frequency matched to cases on age (±5 years)

and race/ethnicity. Controls were identified by a neighborhood walk algorithm which

proceeds through an obligatory sequence of adjacent houses or residential units

beginning at a specific residence that has a specific geographic relationship to the

residence where the case lived at diagnosis.

UTAH: Utah, USThe Utah study consisted of 375 PRCA cases identified through the Utah Cancer

Registry which is part of the Surveillance, Epidemiology and End Results (SEER)

Cancer Registry Program. Cases were selected from high risk pedigrees but are

unrelated. Although all have a family history of PRCA, only 197 have a first degree

relative with PRCA. An additional 132 unrelated controls were selected from other

studies (spouses) who were distributionally age matched and cancer-free. DNA was

obtained from blood samples.

VALAIS: Switzerland in collaboration with Montreal, CanadaBetween December 1, 2002 and January 31, 2007, all urologists in a relatively

isolated alpine region of Switzerland (canton du Valais) invited their patients

diagnosed with invasive PrCa (all stages) to participate to a research project on

genetic factors involved in PrCa. Both parents were required to originate from the

canton du Valais. A detailed family history on at least 3 generations was collected by

a trained research nurse, as well as a blood sampling. A series of healthy men,

without a self-reported family history of PrCa, originating from the same region,

participated as controls (blood donors and elderly patients seen in private practice).

Most of these men had regular PSA screening. This study has contributed DNA

samples to molecular work in Montreal. For this report the genotyping was performed

in the UK on DNA obtained from the Montreal laboratory which was sourced from the

Valais sample set.

Reference List

1. Drieschner,N. et al. A domain of the thyroid adenoma associated gene (THADA) conserved in vertebrates becomes destroyed by chromosomal rearrangements observed in thyroid adenomas. Gene 403, 110-117 (2007).

2. Rippe,V. et al. Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas. Oncogene 22, 6111-6114 (2003).

3. Zeggini,E. et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet. 40, 638-645 (2008).

4. King,T.E. et al. The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS. ONE. 3, e3535 (2008).

5. Wu,M. et al. Cloning and identification of a novel human gene PDLIM5, a homolog of AD-associated neuronal thread protein (AD7c-NTP). DNA Seq. 15, 144-147 (2004).

6. Jankowska,A.M. et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood(2009).

7. bate-Shen,C., Shen,M.M., & Gelmann,E. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 76, 717-727 (2008).

8. Lei,Q. et al. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9, 367-378 (2006).

9. Lee,M.J., Kim,Y.S., Kummar,S., Giaccone,G., & Trepel,J.B. Histone deacetylase inhibitors in cancer therapy. Curr. Opin. Oncol. 20, 639-649 (2008).

10. Chen,H., Nandi,A.K., Li,X., & Bieberich,C.J. NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res. 62, 338-340 (2002).

11. Fu,V.X. et al. Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Res. 68, 6797-6802 (2008).

12. Easton,D.F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087-1093 (2007).

13. Camp,N.J., Farnham,J.M., & Cannon-Albright,L.A. Localization of a prostate cancer predisposition gene to an 880-kb region on chromosome 22q12.3 in Utah high-risk pedigrees. Cancer Res. 66, 10205-10212 (2006).

14. Johanneson,B. et al. Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb. Hum. Genet. 123, 65-75 (2008).

15. Camp,N.J. et al. Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum. Mol. Genet. 16, 1271-1278 (2007).

16. Kote-Jarai,Z. et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol. Biomarkers Prev. 17, 2052-2061 (2008).

17. Meyer,A. et al. Association of chromosomal locus 8q24 and risk of prostate cancer: A hospital-based study of German patients treated with brachytherapy. Urol. Oncol.(2008).

18. Cunningham,J.M. et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol. Biomarkers Prev. 16, 969-978 (2007).

19. Kolonel,L.N. et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am. J. Epidemiol. 151, 346-357 (2000).

20. Park,J.Y. et al. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology 70, 374-379 (2007).

21. Richards,B. et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum. Mol. Genet. 2, 159-163 (1993).

22. Rebbeck,T.R., Jaffe,J.M., Walker,A.H., Wein,A.J., & Malkowicz,S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 90, 1225-1229 (1998).

23. Chambers,S.K. et al. ProsCan for men: randomised controlled trial of a decision support intervention for men with localised prostate cancer. BMC. Cancer 8, 207 (2008).

24. Lai,J. et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 28, 1032-1039 (2007).

25. Fitzgerald,L.M. et al. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk: a replication study in an ethnically homogeneous population. Prostate 68, 1373-1379 (2008).

26. Fitzgerald,L.M. et al. Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease. Eur. J. Hum. Genet.(2008).

UK

The UK Genetic Prostate Cancer Study Collaborators

Listed in supplementary table below

The UK ProtecT Study Collaborators

Prasad Bollina, Sue Bonnington, Debbie Cooper, Andrew Doble, Alan Doherty, Garrett Durkan, Emma Elliott, David Gillatt, Pippa Herbert, Peter Holding, Joanne Howson, Mandy Jones, Roger Kockelbergh, Howard Kynaston, Teresa Lennon, Norma Lyons, Hing Leung, Hilary Moody, Philip Powell, Stephen Prescott, Pauline Thompson, Garrett Durkanc/o Surgical Oncology (Uro-Oncology: S4), University of Cambridge, Box 279, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QQ

THE PRACTICAL CONSORTIUM (in addition to those named in the author list)

UK

UK Genetic Prostate Cancer Study and The Prostate Cancer Research Foundation StudyThe UKGPCS Collaborators – as aboveNote S. Edwards – address as listed until 31.10.08The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, Sutton UKCyril FisherCharles Jameson

University of NottinghamSandra BarrettPenelope Kelham

The ProtecT StudyPaul M. BrownAnne GeorgeGemma MarsdenMichael DavisThe UK ProtecT Study Collaborators – as above

BiPAS, University of Birmingham

Mr David M A Wallace - Queen Elizabeth Medical Centre, Edgbaston, BirminghamMr Alan Doherty - Queen Elizabeth Medical Centre, Edgbaston, BirminghamMr R I Bhatt - Queen Elizabeth Medical Centre, Edgbaston, BirminghamMr K Subramonian - Queen Elizabeth Medical Centre, Edgbaston, BirminghamDr John Arrand – University of BirminghamLouise Flanagan – University of BirminghamSita Ann Bradley - Queen Elizabeth Medical Centre, Edgbaston, Birmingham

Australia

The Melbourne Group TissuPath, Melbourne, AustraliaJohn Pedersen

Cancer Epidemiology Centre, The Cancer Council Victoria

Charmaine SmithMelisa Bagnato

Australian Prostate Cancer Research Centre – QLD and Institute of Health & Biomedical Innovation, Queensland University of Technology incorporating Retrospective Queensland Study

Colleen Nelson Tracy O’Mara Kimberly HinzePatricia VandenBergh Beth Newman David Nicol –Princess Alexandra HospitalJohn Yaxley - Brisbane Private Hospital

The ProsCan Study Megan Ferguson – The Cancer Council QueenslandDavid Nicol – Princess Alexandra HospitalThe Northern Section of the Urological Society of Australia and New ZealandRoyal Brisbane and Women’s HospitalPrincess Alexandra HospitalMater Adults HospitalIpswich HospitalGreenslopes Private HospitalRedlands HospitalRedcliffe HospitalThe Townsville HospitalMackay Base HospitalQEII Hospital

TASPRAC StudyTasmanian Cancer RegistryRoyal Hobart Hospital Launceston General HospitalHobart Pathology

James Stankovich Russell Thomson Liesel FitzGerald Simon Foote David ChallisJohn McArdleJames McKayAnnette BanksRebekah McWhirterKate ButoracHeidi SmarkLeigh Blizzard

Bulgaria

PCMUS studyMedical University – Sofia,

Department of UrologyElenko Popov

Molecular Medicine Center and Department of Chemistry and BiochemistryDarina KachakovaRumjana DodovaOlga BelchevaMomchil NikolovVanio Mitev

Department of General and Clinical PathologyAleksandrina VlahovaTihomir DikovSvetlana ChristovaCanadaThe Montreal StudyNancy HamelKimberley Kotar

ChinaProstate cancer study in Shanghai, ChinaJian-Guo HouDan-Feng XuWen-Jun ChangXing-Xing Xu

FinlandThe Finnish part of European Study of Screening for Prostate Cancer Screening (ERSPC)Ulf-Håkan Stenman

Finnish Genetic Predisposition to Prostate Cancer StudyInstitute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland

Henna MattilaSanna SiltanenSanna PakkanenJarkko Isotalo

Department of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, FinlandMika Matikainen

GermanyUlm

Institut für Humangenetik, Ulm

Harald SurowyMargot BruggerIrina WiestBärbel WeberKlinikum für Urologie und Kinderurologie:

Kathleen HerkommerThomas PaissRainer Kuefer

The Hannover Prostate Cancer Study

Natalia DubrowinskajaChristoph von KlotMarkus KuczykPeter HillemannsMichael BremerJohann H. KarstensStefan Machtens

Switzerland

Prostate Cancer Study in ValaisCédric BiedermannHans-Ulrich PeterNicolas DefabianiSabine BieriChristophe GirardetIsabelle KonzelmannMichèle StalderMarie-Mathilde Meier

US

Mayo ClinicLiang WangJulie Cunningham

University of Michigan Flint Men’s Health StudyKimberly A. ZuhlkeEmilie K. JohnsonJames E. Montie

The Moffitt GroupJames A Haley VA Hospital, Tampa, FL, USA

Babu Zakariah Hyun Y. ParkSelina RadeinMaria RinconBabu Zachariah

Study of Clinical Outcomes, Risk and Ethnicity (SCORE) at the University of Pennsylvania

Charnita Zeigler-JohnsonElaine SpanglerMargerie CoomesStephen GallagherAmy Walker

The UK Genetic Prostate Cancer Study Collaborators

Consultant Hospital Address PostcodeMr N P Cohen Aberdeen Royal Infirmary Foresterhill, Aberdeen AB25 22NMr I Conn Aberdeen Royal Infirmary Foresterhill, Aberdeen AB25 22NMr Kuchibhotla S Swami Aberdeen Royal Infirmary Foresterhill, Aberdeen AB25 22NMr Leslie E F Moffat Aberdeen Royal Infirmary Foresterhill, Aberdeen AB25 22NDr Sue Kenwrick Addenbrooke’s Hospital Hills Road, Cambridge CB2 2QQDr Helen Patterson Addenbrooke’s Hospital Hills Road, Cambridge CB2 2QQDr Katherine Waite Addenbrooke’s Hospital Hills Road, Cambridge CB2 2QQMr A Doble Addenbrooke's Hospital Hills Road, Cambridge CB2 2QQDr Vicki Wiles Addenbrooke's Hospital Hills Road, Cambridge CB2 2QQ

Mr C Irwin Alexandra HospitalWoodrow Drive, Redditch, Worcestershire B98 7UB

Mr M Lancashire Alexandra HospitalWoodrow Drive, Redditch, Worcestershire B98 7UP

Mr B W Ellis Ashford Hospital London Road, AshfordTW15 3AA

Mr Ravi Kulkarni Ashford Hospital London Road, AshfordTW15 3AA

Mr Riza Murat Gurun Ayr HospitalDalmellington Road, Ayr, Scotland KA6 6DX

Mr Graham W Hollins Ayr Hospital

Dalmellington Road, Ayr, Scotland KA6 6DX

Dr Rana Mahmood Ayr HospitalDalmellington Road, Ayr, Scotland KA6 6DX

Mr Robert N Meddings Ayr Hospital

Dalmellington Road, Ayr, Scotland KA6 6DX

Mr Tim Briggs Barnet General Hospital Wellhouse Lane, Barnet, Herts EN5 3DJDr Irene Chong Barnet General Hospital Wellhouse Lane, Barnet, Herts EN5 3DJMr James S Gelister Barnet General Hospital Wellhouse Lane, Barnet, Herts EN5 3DJMr Faiz Mumtaz Barnet General Hospital Wellhouse Lane, Barnet, Herts EN5 3DJMr Ramachandran Ravi

Basildon & Thurrock University Hospitals NHS Trust Nethermayne, Basildon SS16 5NL

Mr Peter R Malone Battle Hospital Oxford Road, Reading, Berkshire RG3 1AG

Mr A Pengelly Battle Hospital Oxford Road, Reading, Berkshire RG3 1AG

Dr David Dodds Beatson Oncology CentreWestern Infirmary, Dumbarton Road, Glasgow G11 6NT

Dr C Featherston Beatson Oncology CentreWestern Infirmary, Dumbarton Road, Glasgow G11 6NT

Mr David Hendry Beatson Oncology CentreWestern Infirmary, Dumbarton Road, Glasgow G11 6NT

Dr Gareth Jones Beatson Oncology CentreWestern Infirmary, Dumbarton Road, Glasgow G11 6NT

Professor David Kirk Beatson Oncology CentreWestern Infirmary, Dumbarton Road, Glasgow G11 6NT

Dr John M Russell Beatson Oncology CentreWestern Infirmary, Dumbarton Road, Glasgow G11 6NT

Dr M Siva Beatson Oncology Centre Western Infirmary, Dumbarton G11 6NT

Road, GlasgowProfessor Mary Leader Beaumont Hospital

Beaumont Road, Dublin, Southern Ireland Dublin 9

Dr Robert J Thomas Bedford HospitalPrimrose Oncology Unit, Kempston Road, Bedford MK42 9DJ

Professor Patrick Morrison Belfast City Hospital

Lisburn Road, Belfast, Northern Ireland BT9 7AB

Professor Joe O'Sullivan Belfast City Hospital

Lisburn Road, Belfast, Northern Ireland BT9 7AB

Dr L Shum Belfast City HospitalLisburn Road, Belfast, Northern Ireland BT9 7AB

Dr D Stewart Belfast City HospitalLisburn Road, Belfast, Northern Ireland BT9 7AB

Mr Jeremy Feggetter Berwick InfirmaryBerwick Upon Tweed, Northumbria TD15 1LT

Mr J O'BrienBirmingham Heartlands Hospital

Bordesley Green East, Birmingham B9 5SS

Dr Trevor Cole Birmingham Women’s HospitalClinical Genetics Unit, Edgbaston, Birmingham B15 2TG

Dr Dorthe Cruger Birmingham Women’s HospitalClinical Genetics Unit, Edgbaston, Birmingham B15 2TG

Professor E R Maher Birmingham Women’s HospitalClinical Genetics Unit, Edgbaston, Birmingham B15 2TG

Mr Donald Neilson Blackburn Royal Infirmary Haslingden Road, Blackburn BB2 3HHMr G D Wemyss-Holden Blackburn Royal Infirmary

Bolton Road, Blackburn, Lancashire BB2 3LR

Mr Shabbir Susnerwala Blackpool Victoria Hospital

Whinney Heys Road, Blackpool, Lancashire FY3 8NR

Dr Amit Bahl Bristol Royal Infirmary Marlborough Street, Bristol BS2 8HWMr Raj Persad Bristol Royal Infirmary Marlborough Street, Bristol BS2 8HWMr Mark Wright Bristol Royal Infirmary Marlborough Street, Bristol BS2 8HW

Ms Angelika Zang Bromley HospitalCromwell Avenue, Bromley, Kent BR2 9AJ

Dr Priscilla Leone Broomfield HospitalCourt Road, Broomfield, Chelmsford, Essex CM1 5ET

Dr Saad Tahir Broomfield HospitalCourt Road, Broomfield, Chelmsford, Essex CM1 5ET

Dr Omi Parikh Burnley General HospitalCasterton Avenue, Burnley, Lancs BB10 2PQ

Mr Jaspal Virdi Capio Rivers HospitalHigh Wych Road, Sawbridgeworth

CM21 0HH

Mr Victor Izegbu Central Middlesex HospitalActon Lane, Park Royal, London

NW10 7NS

Mr James Bellringer Charing Cross Hospital Fulham Palace Road, London W6 8RFMr Timothy J Christmas Charing Cross Hospital Fulham Palace Road, London W6 8RFDr Alison Falconer Charing Cross Hospital Fulham Palace Road, London W6 8RFMr Simon Carter Charing Cross Hospital Fulham Palace Road, London W6 8RFMr D Hrouda Charing Cross Hospital Fulham Palace Road, London W6 8RF

Dr Stephen J Karp Chase Farm HospitalThe Ridgeway, Enfield, Middlesex EN2 8JL

Dr Mark BowerChelsea & Westminster Hospital 368 Fulham Road, London

SW10 9RH

Mr Michael DinneenChelsea & Westminster Hospital 369 Fulham Road, London

SW10 9RH

Dr Cathryn BrockChelsea and Westminster Hospital 370 Fulham Road, London

SW10 9RH

Mr Hugh Gilbert Cheltenham General HospitalSandford Road, Cheltenham, Gloucester GL53 7AN

Dr P Jenkins Cheltenham General HospitalSandford Road, Cheltenham, Gloucester GL53 7AN

Mr Nigel R Boucher Chesterfield Royal Hospital Calow, Chesterfield S44 5BL

Mr Michael J James Chesterfield Royal HospitalCalow, Chesterfield, Derbyshire S44 5BL

Dr Richard Cowan Christie HospitalWilmslow Road, Withington, Manchester M20 4BX

Professor D Gareth Evans Christie Hospital

Wilmslow Road, Withington, Manchester M20 4BX

Dr Jacqueline Livsey Christie HospitalWilmslow Road, Withington, Manchester M20 4BX

Dr John Logue Christie HospitalWilmslow Road, Withington, Manchester M20 4BX

Dr James P Wylie Christie HospitalWilmslow Road, Withington, Manchester M20 4BX

Dr Fiona Lalloo Christie Hospital Wilmslow Road, Withington, Manchester M20 4QL

Dr Elaine Sugden Churchill Hospital Old Road, Headington, Oxford OX3 7LJMr Simon F Brewster Churchill Hospital Old Road, Headington, Oxford OX3 7LJDr David J Cole Churchill Hospital Old Road, Headington, Oxford OX3 7LJDr C Connell Churchill Hospital Old Road, Headington, Oxford OX3 7LJDr Andrew Protheroe Churchill Hospital Old Road, Headington, Oxford OX3 7LJ

Mr M F SaxbyCity General Hospital, Stoke on Trent

Newcastle Road, Stoke-on-Trent ST4 6QG

Mr P G Ryan City Hospital, Birmingham Dudley Road, Birmingham B18 7HQDr David Peake City Hospital, Birmingham Dudley Road, Birmingham B18 7HQ

Dr M CoeClatterbridge Centre for Oncology

Clatterbridge Rd, Bebington, Wirral CH63 4JY

Mr R D ErringtonClatterbridge Centre for Oncology


Dr A IbrahimClatterbridge Centre for Oncology


Dr Isabel SyndikusClatterbridge Centre for Oncology


Professor C M Booth Colchester General HospitalTurner Road, Colchester, Essex CO4 5JL

Mr John Corr Colchester General HospitalTurner Road, Colchester, Essex CO4 5JL

Mr Michael Lynch Colchester General HospitalTurner Road, Colchester, Essex CO4 5JL

Mr P S Callaghan Conquest Hospital The Ridge, St Leonards on Sea, Hastings, East Sussex TN37 7RD

Mr R Plail Conquest Hospital The Ridge, St Leonards on Sea, Hastings, East Sussex TN37 7RD

Dr D Ash Cookridge Hospital Hospital Lane, Leeds LS16 6QB

Dr C Coyle Cookridge Hospital Hospital Lane, Leeds LS16 6QB Dr David Bottomley Cookridge Hospital Hospital Lane, Leeds LS16 6QBMr Christopher Powell Countess of Chester Hospital Liverpool Road, Chester CH2 1ULMr Christopher Chilton Derby City General Hospital Uttoxeter Road, Derby DE22 3NEMr Mike Henley Derby City General Hospital Uttoxeter Road, Derby DE22 3NEMr A M Peracha Derby City General Hospital Uttoxeter Road, Derby DE22 3NEMr John H Williams Derby City General Hospital Uttoxeter Road, Derby DE22 3NEMr Simon Williams Derby City General Hospital Uttoxeter Road, Derby DE22 3NEDr D Muthukumar Derbyshire Royal Infirmary London Road, Derby DE1 2QYMr Stephen A Thomas Derbyshire Royal Infirmary London Road, Derby DE1 2QYMr Andrew J Dickinson Derriford Hospital Derriford Road, Plymouth PL6 8DHMr John Hammonds Derriford Hospital Derriford Road, Plymouth PL6 8DHMr Paul McInerney Derriford Hospital Derriford Road, Plymouth PL6 8DHDr Sarah Pascoe Derriford Hospital Derriford Road, Plymouth PL6 8DHMr Henry Sells Derriford Hospital Derriford Road, Plymouth PL6 8DHDr C J Tyrell Derriford Hospital Derriford Road, Plymouth PL6 8DH

Mr Stuart F TindallDiana Princess of Wales Hospital Scartho Road, Grimsby DN33 2BA

Mr N Afzal Dorset County Hospital Williams Avenue, Dorchester DT1 2JYMr Steven Andrews Dorset County Hospital Williams Avenue, Dorchester DT1 2JYMr Andrew J Cornaby Dorset County Hospital Williams Avenue, Dorchester DT1 2JY

Mr J A A Archbold Downe Hospital9A Pound Lane, Down Patrick, Co Downe BT30 6JA

Dr Ian H KunklerDumfries & Galloway Royal Infirmary Bankend Road, Dumfries DG1 4AP

Dr A Folkes East Surrey Hospital Canada Ave, Redhill, Surrey RH1 5RHDr Julian Money-Kyrle East Surrey Hospital Canada Ave, Redhill, Surrey RH1 5RH

Dr N A BaxEastbourne District General Hospital

King's Drive, Eastbourne, East Sussex

BN21 2UD

Mr W T LawrenceEastbourne District General Hospital


BN21 2UD

Dr F McKinnaEastbourne District General Hospital

Eastern Road, Brighton, East Sussex BN2 5BE

Mr Peter R Rimington

Eastbourne District General Hospital


BN21 2UD

Mr Chris Dawson Edith Cavell HospitalBretton Gate, Peterborough, Cambridgeshire PE3 9GZ

Mr F Khan Edith Cavell HospitalBretton Gate, Peterborough, Cambridgeshire PE3 9GZ

Mr C Charig Epsom General Hospital Dorking Road, Epsom, Surrey KT18 7EGMr Pieter J Le Roux Epsom General Hospital Dorking Road, Epsom, Surrey KT18 7EG

Mr Michael HehirFalkirk & District Royal Infirmary Major's Loan, Falkirk, Scotland FK1 5QE

Mr Michael F SmithFalkirk & District Royal Infirmary Major's Loan, Falkirk, Scotland FK1 5QE

Mr James TweedleFalkirk & District Royal Infirmary Major's Loan, Falkirk, Scotland FK1 5QE

Mr James Glenister Finchley Memorial HospitalGranville Road, North Finchley, London N12 0JE

Mr C D Eden Frimley Park HospitalPortsmouth Road, Frimley, Camberley GU16 7UJ

Mr Stephen E M Langley Frimley Park Hospital

Portsmouth Road, Frimley, Camberley GU16 7UJ

Mr Bruce Montgomery Frimley Park Hospital

Portsmouth Road, Frimley, Camberley GU16 5UJ

Mr Harry Naerger Frimley Park HospitalPortsmouth Road, Frimley, Camberley GU16 5UJ

Mr Edward Palfrey Frimley Park HospitalPortsmouth Road, Frimley, Camberley GU16 7UJ

Mr Richard Wilson Furness General Hospital Dalton Lane, Barrow in Furness LA14 4LF

Mr Khaver N Qureshi Gartnavel General Hospital

1053 Great Western Road, Glasgow G12 0YN

Mr Ike Apakama George Elliott HospitalCollege Street, Nuneaton, Warks CV10 7BL

Mr Krishna Prasad George Elliott HospitalCollege Street, Nuneaton, Warks CV10 7BL

Dr Al-Samerraie Glan Clwyd Hospital Bodelwyddan, Rhyl, Wales LL18 5UJDr Louise Emmerson Glan Clwyd Hospital Bodelwyddan, Rhyl, Wales LL18 5UJDr A Nethersell Glan Clwyd Hospital Bodelwyddan, Rhyl, Wales LL18 5UJMr Srinivasan Glan Clwyd Hospital Bodelwyddan, Rhyl, Wales LL18 5UJ

Dr John Glaholm Good Hope HospitalRectory Road, Sutton Coldfield, West Midlands B75 7RR

Mr Hemant Ohja Good Hope Hospital Rectory Road, Sutton Coldfield, West Midlands B75 7RR

Mr Nazeer Dahar Grantham & District Hospital101 Manthorpe Road, Grantham, Lincs

NG31 8DG

Mr Pallon Daruwala Grantham & District Hospital101 Manthorpe Road, Grantham, Lincs

NG31 8DG

Mr Rupert Beck Great Western HospitalMarlborough Road, Swindon, Wilts SN3 6BB

Mr John W Iacovou Great Western HospitalMarlborough Road, Swindon, Wilts SN3 6BB

Dr Peter Harper Guy’s Hospital St Thomas Street, London SE1 9RTDr Matthew Perry Guy’s Hospital St Thomas Street, London SE1 9RTMr Rick Popert Guy’s Hospital St Thomas Street, London SE1 9RTMr D Cahill Guy's Hospital St Thomas Street, London SE1 9RTDr H Jane Dobbs Guy's Hospital St Thomas Street, London SE1 9RTDr Louise Izatt Guy's Hospital St Thomas Street, London SE1 9RTMr Tim S O'Brien Guy's Hospital St Thomas Street, London SE1 9RTDr Tong Guy's Hospital St Thomas Street, London SE1 9RTMr Anand R Kelkar Hammersmith Hospital Du Cane Road, London W12 0HSProfessor J H Waxman Hammersmith Hospital Du Cane Road, London W12 0HS

Mr David BadenochHarley Street Consulting Rooms 101 Harley Street, London W1G 6AH

Mr Neil O'DonoghueHarley Street Consulting Rooms 99 Harley Street, London W1G 6AQ

Mr Pravin Singh Harrogate District Hospital Lancaster Park Road, HG2 7SX

Harrogate

Miss Anne Lawson Harrogate District Hospital Lancaster Park Road, Harrogate HG2 7SX

Mr M PancharatnamHemel Hempstead General Hospital

Hillfield Road, Hemel Hempstead, Herts HP2 4AD

Dr Nihil ShahHemel Hempstead General Hospital

Hillfield Road, Hemel Hempstead, Herts HP2 4AD

Mr Graham M Sole Hereford County Hospital Union Walk, Hereford HR1 2ER Mr A J Pope Hillingdon Hospital Pield Heath Road, Uxbridge UB8 3NNMr Noel W Clarke Hope Hospital Stott Lane, Salford M6 8HDMr Michael Ferro Huddersfield Royal Infirmary Lindley, Huddersfield HD3 3EAMr John M Harney Huddersfield Royal Infirmary Lindley, Huddersfield HD3 3EA

Dr S Fiona DouglasInstitute of Human Genetics International Centre for Life

Central Parkway, Newcastle upon Tyne NE1 3BZ

Mr G Banerjee Ipswich Hospital Heath Road, Ipswich, Suffolk IP4 5PDMr P Donaldson Ipswich Hospital Heath Road, Ipswich, Suffolk IP4 5PDDr Christopher Scrase Ipswich Hospital Heath Road, Ipswich, Suffolk IP4 5PD

Mr David ChadwickJames Cook University Hospital

Department of Urology, Marton Road, Middlesbrough TS4 3BW

Dr P D John Hardman

James Cook University Hospital


Mr John R Hindmarsh

James Cook University Hospital


Mr Gokarakonda Suresh James Paget Hospital

Lowestoft Road, Gorleston, Great Yarmouth, Norfolk NR31 6LA

Dr Natasha Mithal Kent & Canterbury Hospital Ethelbert Road, Canterbury, Kent CT1 3NG

Mr Keith W Murray Kent & Canterbury Hospital Ethelbert Road, Canterbury, Kent CT1 3NG

Mr Owen W Davison Kettering General HospitalRothwell Road, Kettering, Northants NN16 8UZ

Mr D Baxter-Smith Kidderminster HospitalBewdley Road, Kidderminster, Worcs DY11 6RJ

Mr Hanif Motiwala King Edward VII Hospital Windsor, Berkshire SL4 3DPDr N Barber King’s College Hospital Denmark Hill, London SE5 9RSMr Gordon Muir King’s College Hospital Denmark Hill, London SE5 9RS

Mr Robert F Copland Kings Oak Private HospitalChase Farm (North Side), The Ridgeway, Enfield EN2 8SD

Mr John Dick Kingston HospitalGalsworthy Road, Kingston-upon-Thames, Surrey KT2 7QB

Mr Roland Morley Kingston HospitalGalsworthy Road, Kingston-upon-Thames, Surrey KT2 7QB

Mr Alan Thompson Kingston HospitalGalsworthy Road, Kingston-upon-Thames, Surrey KT2 7QB

Dr Nicholas Van As Kingston HospitalGalsworthy Road, Kingston-upon-Thames, Surrey KT2 7QB

Mr Paul C Butterworth Leicester General Hospital Gwendolen Road, Leicester LE5 4PWMr Thomas R L Griffiths Leicester General Hospital Gwendolen Road, Leicester LE5 4PWMr Roger Kockelbergh Leicester General Hospital Gwendolen Road, Leicester LE67 4DE

Mr David Osborn Leicester General Hospital Gwendolen Road, Leicester LE5 4PWMr T Terry Leicester General Hospital Gwendolen Road, Leicester LE5 4PW

Mr Julian Barwell Leicester Royal Infirmary Infirmary Square, Leicester LE1 5WW

Professor Richard C Trembath

Leicester Royal Infirmary (Now at King's College Hospital, London, SE5 9RS) Infirmary Square, Leicester LE1 5WW

Mr Pradip Javle Leighton Hospital Middlewich Road, Crewe, Cheshire CW1 4QT

Mr Pradip Basu Lincoln County Hospital Greetwell Road, Lincoln LN2 5QYMr I Mark Lincoln County Hospital Greetwell Road, Lincoln LN2 5QYDr Miguel Panades Lincoln County Hospital Greetwell Road, Lincoln LN2 5QYDr Thiagarajan Sreenivasan Lincoln County Hospital

Cliff Gardens, Scunthorpe, N Lincolnshire

DN15 7BH

Mr Damien C Hanbury Lister Hospital

Corey’s Mill Lane, Stevenage, Herts SG1 4AB

Mr T A McNicholas Lister Hospital Corey’s Mill Lane, Stevenage, Herts SG1 4AB

Dr S DavidsonMacclesfield District General Hospital

Victoria Road, Macclesfield, Cheshire SK10 3BL

Mr David HoldenMacclesfield District General Hospital


Mr Siva Namasivayam

Macclesfield District General Hospital


Mr Paul J Reddy Maidstone HospitalHermitage Lane, Maidstone, Kent M16 9QQ

Dr Sharon Beesley Maidstone Hospital Hermitage Lane, Kent ME16 9QQ

Mr Trevor F Ford Maidstone HospitalHermitage Lane, Barming, Kent

ME16 9QQ

Mr J Lewis Maidstone HospitalHermitage Lane, Barming, Kent

ME16 9QQ

Dr Anula D Chetiyawardana Manor Hospital

Moat Road, Walsall, West Midlands WS2 9PS

Mr James Smith Mater Hospital 47-51 Crumlin Road, Belfast BT14 6ABMr Gulzar Mufti Medway Maritime Hospital Windmill Road, Gillingham ME7 5NY

Mr Henry Andrews Milton Keynes General HospitalStanding Way, Eaglestone, Milton Keynes MK6 5LD

Mr E M Walker Milton Keynes General HospitalStanding Way, Eaglestone, Milton Keynes MK6 5LD

Mr Iqbal Anjum Milton Keynes General Hospital Standing Way, Eaglestone, Milton Keynes MK6 5LD

Mr Pradeep Bose Morriston Hospital Morriston, Swansea, Wales SA6 6NLMr Malcolm G Lucas Morriston Hospital Morriston, Swansea, Wales SA6 6NLDr Richard F U Ashford

Mount Vernon Centre for Cancer Treatment

Rickmansworth Road, Northwood, Middlesex HA6 2RN

Dr Jeanette DicksonMount Vernon Centre for Cancer Treatment


Professor Peter Hoskin

Mount Vernon Centre for Cancer Treatment


Dr Rob HughesMount Vernon Centre for Cancer Treatment


Dr Peter Ostler Mount Vernon Centre for Rickmansworth Road, HA6 2RN

Cancer Treatment Northwood, Middlesex

Dr Mark J Churn New Cross Hospital

Wednesfield Road, Wolverhampton, West Midlands

WV10 0QP

Mr Peter Cooke New Cross Hospital


WV10 0QP

Mr John A Inglis New Cross Hospital


WV10 0QP

Mr N H Philp New Cross Hospital


WV10 0QP

Mr Brian Waymont New Cross Hospital


WV10 0QP

Mr Hing Leung Newcastle General HospitalWestgate Road, Newcastle-upon-Tyne NE4 6BE

Dr Rhona McMenemin Newcastle General Hospital

Westgate Road, Newcastle-upon-Tyne NE4 6BE

Dr I Pedley Newcastle General HospitalWestgate Road, Newcastle-upon-Tyne NE4 6BE

Dr J Trevor Roberts Newcastle General Hospital Westgate Road, Newcastle-upon-Tyne NE4 6BE

Mr J O Lee Noble's HospitalWestmorland Road, Douglas, Isle of Man IM1 4QA

Mr Edwin T S HoNorfolk & Norwich University Hospital Colney Lane, Norwich NR4 7UZ

Mr Stuart IrvingNorfolk & Norwich University Hospital Colney Lane, Norwich NR4 7UZ

Mr Robert MillsNorfolk & Norwich University Hospital Colney Lane, Norwich NR4 7UZ

Mr Krishna K SethiaNorfolk & Norwich University Hospital Colney Lane, Norwich NR4 7UZ

Mr Ralph J WebbNorfolk & Norwich University Hospital Colney Lane, Norwich NR4 7UZ

Dr Denise J Sheehan North Devon District Hospital Raleigh Park, Barnstaple EX31 4JBMr Douglas G Barnes

North Manchester General Hospital

Delauneys Road, Crumpsall, Manchester M8 5RB

Mr Wai-Man ChowNorth Manchester General Hospital

Delaunays Road, Crumpsall, Manchester M8 5RB

Mr C B CostelloNorth Manchester General Hospital

Delauneys Road, Crumpsall, Manchester M8 5RB

Dr Christine Elwell Northampton General Hospital Billing Rd, Northampton NN1 5BDMr Jeremy Elkabir Northwick Park Hospital Watford Road, Harrow HA1 3UJDr D Fermont Northwick Park Hospital Watford Road, Harrow HA1 3UJMr A David Mee Northwick Park Hospital Watford Road, Harrow HA1 3UJMr M Bishop Nottingham City Hospital Hucknall Road, Nottingham NG5 1PBMr O Cole Nottingham City Hospital Hucknall Road, Nottingham NG5 1PBMr D R Harriss Nottingham City Hospital Hucknall Road, Nottingham NG5 1PBDr R John Lemburger Nottingham City Hospital Hucknall Road, Nottingham NG5 1PB

Dr Michael Sokal Nottingham City Hospital Hucknall Road, Nottingham NG5 1PBDr Santhanam Sundar Nottingham City Hospital

Mansfield Road, Sutton in Ashfield NG17 4JL

Mr Michael Dunn Nottingham Nuffield Hospital748 Mansfield Road, Woodthorpe, Nottingham NG5 3FZ

Mr Graeme H Urwin Nuffield Hospital York Haxby Road, York YO31 8TA

Dr Richard Benson Peterborough District HospitalThorper Road, Peterborough, Cambridgeshire PE3 6DA

Dr Baria Pilgrim Hospital Sibsey Road, Boston, Lincs PE21 9QSMr Memon Pilgrim Hospital Sibsey Road, Boston PE21 9QS

Mr C Shekhar Biyani Pinderfields HospitalAberford Road, Wakefield, West Yorkshire WF1 4DG

Mr Tony J Browning Pinderfields HospitalAberford Road, Wakefield, West Yorkshire WF1 4DG

Mr Michael Murphy Pinderfields HospitalAberford Road, Wakefield, West Yorkshire WF5 4DG

Mr S K Sundaram Pinderfields HospitalAberford Road, Wakefield, West Yorkshire WF1 4DG

Mr P M T Weston Pinderfields HospitalAberford Road, Wakefield, West Yorkshire WF1 4DG

Dr Thomas D Goode Poole General Hospital Longfleet Road, Poole BH15 2JBDr Tamas Hickish Poole General Hospital Longfleet Road, Poole BH15 2JB

Dr Bruce M Castle Princess Anne HospitalCoxford Rd, Southampton, Hants SO16 5YA

Mr Cummings Princess Anne HospitalCoxford Rd, Southampton, Hants SO16 5YA

Professor Diana Eccles Princess Anne Hospital

Coxford Rd, Southampton, Hants SO16 5YA

Mr N Harvey-Hills Princess Margaret HospitalOsborne Road, Windsor, Berks SL4 3SJ

Dr Diana Mort Princess of Wales Hospital Coity Road, BridgendCF31 1RQ

Mr Pravin Menzes Princess Royal Hospital Lewes Road, Haywards Heath, West Sussex RH16 4EX

Mr Munir AhmedPrincess Royal University Hospital

Farnborough Common, Orpington, Kent BR6 8ND

Mr Guy DawkinsPrincess Royal University Hospital

Farnborough Common, Orpington, Kent BR6 8ND

Mr R I Bhatt Queen Elizabeth Hospital

Queen Elizabeth Medical Centre, Edgbaston, Birmingham B15 2TH

Mr Alan Doherty Queen Elizabeth Hospital


Dr A El-Modir Queen Elizabeth Hospital


Mr Michael Hughes Queen Elizabeth Hospital


Mr C J Luscombe Queen Elizabeth Hospital


Mr David M A Queen Elizabeth Hospital Queen Elizabeth Medical B15 2TH

WallaceCentre, Edgbaston, Birmingham

Professor N James Queen Elizabeth Hospital


Mr K Subramonian Queen Elizabeth Hospital


Mr S J HampsonQueen Mary's University Hospital Roehampton Lane, London

SW15 5PN

Dr Stephanie Gibbs Queen's Hospital Rom Valley Way, Romford RM7 0AG

Dr P Chakraborti Queens Hospital Burton Belvedere Road, Burton-On-Trent, Derbyshire DE13 0RB

Mr M Kumar Queens Hospital Burton Belvedere Road, Burton-On-Trent, Derbyshire DE13 0RB

Dr D Whillis Raigmore HospitalPerth Road, Inverness, Scotland IV2 3UJ

Mr Mohamed Kourah Rochdale Infirmary

Whitehall Street, Rochdale, Greater Manchester OL12 0NB

Mr Bohdan T Parys Rotherham General Hospital Moorgate Road, Rotherham S60 2UDMr Maurice W Lau Royal Albert Edward Infirmary Wigan Lane, Wigan WN1 2NN

Dr Richard Brown Royal Berkshire HospitalLondon Road, Reading, Berkshire RG1 5AN

Mr Derek Fawcett Royal Berkshire HospitalLondon Road, Reading, Berkshire RG1 5AN

Mr P B Rogers Royal Berkshire HospitalLondon Road, Reading, Berkshire RG1 5AN

Ms L Lee Royal Bolton HospitalMinerva Road, Farnworth, Bolton, Lancs BL4 0JR

Ms Gillian E Mobb Royal Bolton HospitalMinerva Road, Farnworth, Bolton, Lancs BL4 0JR

Mr Michalakis L Pantelides Royal Bolton Hospital

Minerva Road, Farnworth, Bolton, Lancs BL4 0JR

Mr F James Bramble Royal Bournemouth Hospital Castle Lane East, Bournemouth, Dorset BH7 7DW

Dr Sue Brock Royal Bournemouth Hospital Castle Lane East, Bournemouth, Dorset BH7 7DW

Mr Charles J M Carter Royal Bournemouth Hospital

Castle Lane East, Bournemouth, Dorset BH7 7DW

Dr Joseph Davies Royal Bournemouth Hospital Castle Lane East, Bournemouth, Dorset BH7 7DW

Ms Donna McBride Royal Bournemouth Hospital Castle Lane East, Bournemouth, Dorset BH7 7DW

Mr John Rundle Royal Bournemouth Hospital Castle Lane East, Bournemouth, Dorset BH7 7DW

Mr Andrew Wedderburn Royal Bournemouth Hospital

Castle Lane East, Bournemouth, Dorset BH7 7DW

Dr Matthew Collinson Royal Cornwall Hospital Treliske, Truro, Cornwall TR1 3LJMr Robert Cox Royal Cornwall Hospital Treliske, Truro, Cornwall TR1 3LJDr R Ellis Royal Cornwall Hospital Treliske, Truro, Cornwall TR1 3LJDr R Newton Royal Cornwall Hospital Treliske, Truro, Cornwall TR1 3LJDr J S O'Rourke Royal Cornwall Hospital Treliske, Truro, Cornwall TR1 3LJ

Dr Alastair H Thomson Royal Cornwall Hospital Treliske, Truro, Cornwall TR1 3LJDr Duncan Wheatley Royal Cornwall Hospital Treliske, Truro, Cornwall TR1 3LJMr Mark A Stott Royal Devon & Exeter Hospital Barrack Rd, Exeter, Devon EX2 5DW Mr Richard D Pocock Royal Devon & Exeter Hospital Barrack Rd, Exeter, Devon EX2 5DW Dr Julia Rankin Royal Devon & Exeter Hospital Barrack Rd, Exeter, Devon EX2 5DW Mr Malcolm Crundwell

Royal Devon and Exeter Hospital Barrack Road, Exeter EX2 5DW

Mr Amir Kaisary Royal Free Hospital Pond Street, London NW3 2QGDr Katharine Pigott Royal Free Hospital Pond Street, London NW3 2QGMr Christopher A Bates Royal Gwent Hospital Cardiff Road, Newport,Gwent NP20 2UBMs Gail Beese Royal Gwent Hospital Cardiff Road, Newport,Gwent NP9 2UBMr W G Bowsher Royal Gwent Hospital Cardiff Road, Newport,Gwent NP9 2UBDr Adam C Carter Royal Gwent Hospital Cardiff Road, Newport,Gwent NP9 2UBMr Richard L Gower Royal Gwent Hospital Cardiff Road, Newport,Gwent NP9 2UBProfessor F C Hamdy

Royal Hallamshire Hospital (Now at University of Oxford) Glossop Road, Sheffield S10 2JF

Mr John Anderson Royal Hallamshire Hospital Glossop Road, Sheffield S10 2JF

Mr G S M HarrisonRoyal Hampshire County Hospital

Romsey Road, Winchester, Hants

SO22 5DG

Mr Andrew Adamson Royal Hampshire HospitalRomsey Road, Winchester, Hants

SO22 5DG

Mr Peter Duffy Royal Lancaster InfirmaryAshton Road, Lancaster, Lancashire LA1 4RP

Mr Carl Rowbotham Royal Lancaster InfirmaryAshton Road, Lancaster, Lancashire LA1 4RP

Mr K A WoolfendenRoyal Liverpool University Hospital Prescot Street, Liverpool L7 8XP

Mr P A CornfordRoyal Liverpool University Hospital Prescot Street, Liverpool L7 8XP

Ms E BancroftRoyal Marsden NHS Foundation Trust Fulham Road, London SW3 6JJ

Professor David Dearnaley

Royal Marsden NHS Foundation Trust Fulham Road, London SW3 6JJ

Dr Robert HuddartRoyal Marsden NHS Foundation Trust Sutton Surrey SM2 5PT

Dr Sameer JhavarRoyal Marsden NHS Foundation Trust Fulham Road, London SW3 6JJ

Dr Vincent KhooRoyal Marsden NHS Foundation Trust Fulham Road, London SW3 6JJ

Dr Imogen LockeRoyal Marsden NHS Foundation Trust Fulham Road, London SW3 6JJ

Dr Anita MitraRoyal Marsden NHS Foundation Trust Fulham Road, London SW3 6JJ

Dr Chris ParkerRoyal Marsden NHS Foundation Trust Sutton Surrey SM2 5PT

Dr Sue ShanleyRoyal Marsden NHS Foundation Trust Fulham Road, London SW3 6JJ

Professor C Woodhouse

Royal Marsden NHS Foundation Trust Fulham Road, London SW3 6JJ

Dr Chris Wynne Royal Marsden NHS Fulham Road, London SM2 5PT

Foundation TrustProfessor Alan Horwich

Royal Marsden NHS Foundation Trust Sutton Surrey SM2 5PT

Mr Chris OgdenRoyal Marsden NHS Foundation Trust Fulham Road, London SW3 6JJ

Prof Cyril FisherRoyal Marsden NHS Foundation Trust Fulham Road, London SW3 6JJ

Dr Charles JamesonRoyal Marsden NHS Foundation Trust Fulham Road, London SW3 6JJ

Mr Neerah K Sharma Royal Oldham Hospital

Rochdale Road, Oldham, Greater Manchester OL1 2JH

Dr Alison Birtle Royal Preston HospitalSharoe Green Lane North, Fulwood, Preston, Lancashire PR2 9HT

Mr Mokete Royal Preston HospitalSharoe Green Lane North, Fulwood, Preston, Lancashire PR2 9HT

Dr Narasimhan Ragavan Royal Preston Hospital

Sharoe Green Lane North, Fulwood, Preston, Lancashire PR2 9HT

Dr Read Royal Preston HospitalSharoe Green Lane North, Fulwood, Preston, Lancashire PR2 9HT

Mr M E Watson Royal Preston HospitalSharoe Green Lane North, Fulwood, Preston, Lancashire PR2 9HT

Dr Marcus Wise Royal Preston HospitalSharoe Green Lane North, Fulwood, Preston, Lancashire PR2 9HT

Miss Rosemary Blades Royal Preston Hospital


Mr Shyam Matenhelia Royal Preston Hospital


Mr Christopher Beacock Royal Shrewsbury Hospital Mytton Oak Road, Shrewsbury SY3 8XQMr Andrew W S Elves Royal Shrewsbury Hospital Mytton Oak Road, Shrewsbury SY3 8XQDr Narayanan N Srihari Royal Shrewsbury Hospital Mytton Oak Road, Shrewsbury SY3 8XQ

Mr Brian Birch Royal South Hants HospitalThe Wessex Rt Centre,St Mary’s Road, Southampton

SO14 0YG

Dr Catherine M Heath Royal South Hants Hospital

The Wessex Rt Centre,St Mary’s Road, Southampton

SO14 0YG

Dr Robert Laing Royal Surrey County Hospital Egerton Road, Guildford GU2 5XXDr David J Bloomfield Royal Sussex County Hospital


Mr C Coker Royal Sussex County HospitalEastern Road, Brighton, East Sussex BN2 5BE

Dr George P Deutsch Royal Sussex County Hospital


Mr Matthew Fletcher Royal Sussex County HospitalEastern Road, Brighton, East Sussex BN2 5BE

Mr T R Larner Royal Sussex County HospitalEastern Road, Brighton, East Sussex BN2 5BE

Dr Shirley Murrell Royal Sussex County HospitalEastern Road, Brighton, East Sussex BN2 5BE

Mr Nawrocki Royal Sussex County HospitalEastern Road, Brighton, East Sussex BN2 5BE

Dr Angus Robinson Royal Sussex County HospitalEastern Road, Brighton, East Sussex BN2 5BE

Dr Marie Wilkins Royal Sussex County HospitalEastern Road, Brighton, East Sussex BN2 5BE

Dr Olivera Frim Royal United Bath Hospital Combe Park, Bath BA1 3AGMr Christopher Gallegos Royal United Bath Hospital Combe Park, Bath BA1 3NGMr Graham P Howell Royal United Bath Hospital Combe Park, Bath BA1 3NGMr Jonathan McFarlane Royal United Bath Hospital Combe Park, Bath BA1 3AGDr Hugh Newman Royal United Bath Hospital Combe Park, Bath BA1 3AG

Dr Ali Samanci Russells Hall HospitalWednesfield Road, Wolverhampton

WV10 0QP

Mr Alister Campbell Salisbury District Hospital Odstock Road, Salisbury, Wilts SP2 8BJMr Peter J Guy Salisbury District Hospital Odstock Road, Salisbury, Wilts SP2 8BJMr Gregor McIntosh Salisbury District Hospital Odstock Road, Salisbury, Wilts SP2 8BJ

Dr C Hamilton Scarborough General HospitalWoodlands Drive, Scarborough YO12 6QL

Mr Simon Hawkyard Scarborough General HospitalWoodlands Drive, Scarborough YO12 6QL

Mr Andrew Robertson Scarborough General Hospital

Woodlands Drive, Scarborough YO12 6QL

Mr L Coombs Scunthorpe General HospitalCliff Gardens, Scunthorpe, N Lincolnshire

DN15 7BH

Dr Sanjay Dixit Scunthorpe General HospitalCliff Gardens, Scunthorpe, N Lincolnshire

DN15 7BH

Mr Sean B Morris Solihull HospitalLode Lane, Solihull, West Midlands B91 2JL

Mr Andrew J Ball Southend University HospitalPrittlewell Chase, Westcliff on Sea, Essex SS0 0RY

Mr T W Carr Southend University HospitalPrittlewell Chase, Westcliff on Sea, Essex SS0 0RY

Dr O Koreich Southend University HospitalPrittlewell Chase, Westcliff on Sea, Essex SS0 0RY

Mr Richard Lodge Southend University HospitalPrittlewell Chase, Westcliff on Sea, Essex SS0 0RY

Mr J W Prejbisz Southend University HospitalPrittlewell Chase, Westcliff on Sea, Essex SS0 0RY

Dr Anne C Robinson Southend University HospitalPrittlewell Chase, Westcliff on Sea, Essex SS0 0RY

Professor Paul H Abrams Southmead Hospital

Westbury-on-Trym, Bristol, Somerset BS10 5NB

Mr Corolis Southmead HospitalWestbury-on-Trym, Bristol, Somerset BS10 5NB

Mr Drake Southmead HospitalWestbury-on-Trym, Bristol, Somerset BS10 5NB

Mr David Gillatt Southmead HospitalWestbury-on-Trym, Bristol, Somerset BS10 5NB

Dr John Graham Southmead HospitalWestbury-on-Trym, Bristol, Somerset BS10 5NB

Mr Rowe Southmead HospitalWestbury-on-Trym, Bristol, Somerset BS10 5NB

Mr F X Keeley Southmead Hospital Westbury-on-Trym, Bristol, Somerset BS10 5NB

Mr McGrath Southmead Hospital Westbury-on-Trym, Bristol, BS10 5NB

SomersetMr Hartwig Schwaibold Southmead Hospital

Westbury-on-Trym, Bristol, Somerset BS10 5NB

Mr Sean Vesey Southport & Formby DGH Town Lane, Southport PR8 6PNDr A Thurston St Albans City Hospital Waverley Road, St Albans AL3 5PNMr Nicholas A Watkin St Anthony's Hospital London Road, North Cheam SM3 9DWMr F I Chinegwundoh St Bartholomew’s Hospital West Smithfield, London

EC1A 7BE

Ms A Lee St Bartholomew’s Hospital West Smithfield, London EC1A 7BE

Dr Graeme H M Mair St Bartholomews Hospital West Smithfield, London EC1A 7BE

Mr Vinod Nargund St Bartholomews Hospital West Smithfield, London EC1A 7BE

Professor Tim Oliver St Bartholomews Hospital West Smithfield, London EC1A 7BE

Dr P Nicholas Plowman St Bartholomews Hospital West Smithfield, London

EC1A 7BE

Mr Ken Anson St George’s Hospital Blackshaw Road, Tooting, London

SW17 0RE

Professor Shirley Hodgson St George’s Hospital

Blackshaw Road, Tooting, London

SW17 0RE

Dr Anand K Saggar St George’s Hospital Blackshaw Road, Tooting, London

SW17 0RE

Mr M J Bailey St George's HospitalBlackshaw Road, Tooting, London

SW17 0QT

Ms E M Gordon St George's HospitalBlackshaw Road, Tooting, London

SW17 0QT

Dr John W Taylor St George's HospitalBlackshaw Road, Tooting, London

SW17 0QT

Mr P J R Boyd St Helier HospitalWrythe Green Lane,Carshalton, Surrey SM5 1AA

Mr Chris R Jones St Helier HospitalWrythe Green Lane,Carshalton, Surrey SM5 1AA

Mr Roger Walker St Helier HospitalWrythe Green Lane,Carshalton, Surrey SM5 1AA

Dr Shelagh Joss St James' University Hospital Ashley Wing, Beckett Street, Leeds LS9 7TF

Mr P Whelan St James' University Hospital Beckett Street, Leeds, West Yorkshire LS9 7TF

Dr F Aparcia St James's University HospitalBeckett Street, Leeds, West Yorkshire LS9 7TF

Ms Liz Hudson St James's University HospitalBeckett Street, Leeds, West Yorkshire LS9 7TF

Mr Stephen Prescott St James's University HospitalBeckett Street, Leeds, West Yorkshire LS9 7TF

Mr Anup Patel St Mary’s Hospital, LondonPraed Street, Paddington, London W2 1NY

Mr Simon A V Holmes St Mary’s Hospital. Portsmouth Milton Road, Portsmouth PO3 6ADMr W D Dunsmuir St Peter's Hospital Chertsey KT16 0PZProfessor Ronald P St Thomas's Hospital Lambeth Palace Road, SE1 7EH

Beaney London

Dr Frances Calman St Thomas's HospitalLambeth Palace Road, London SE1 7EH

Mr Jonathan M Glass St Thomas's Hospital

Lambeth Palace Road, London SE1 7EH

Dr R Simcock St Thomas's HospitalLambeth Palace Road, London SE1 7EH

Mr R Lester James Staffordshire General HospitalWeston Road, Stafford, Staffordshire ST16 3SA

Mr Y Rao Staffordshire General HospitalWeston Road, Stafford, Staffordshire ST16 3SA

Dr John E Scoble Staffordshire General HospitalWeston Road, Stafford, Staffordshire ST16 3SA

Mr A Adeyoju Stepping Hill HospitalPoplar Grove, Stockport, Cheshire SK2 7JE

Mr Stephen Brown Stepping Hill HospitalFountain Street, Ashton-Under-Lyne OL6 9RW

Mr Gerald Collins Stepping Hill Hospital Poplar Grove, Stockport SK2 7JE

Mr Neil Oakley Stepping Hill HospitalPoplar Grove, Stockport, Cheshire SK2 7JE

Mr P O'Reilly Stepping Hill HospitalPoplar Grove, Stockport, Cheshire SK2 7JE

Mr S Lloyd Stirling Royal Infirmary Livilands, Stirling FK8 2AUDr Christopher Alcock Stoke Mandeville Hospital

Mandeville Road, Aylesbury, Buckinghamshire HP21 8AL

Mr Jonathan Greenland Stoke Mandeville Hospital

Mandeville Road, Aylesbury, Buckinghamshire HP21 8AL

Mr Damian Green Sunderland Royal HospitalKayll Road, Sunderland, Tyne and Wear SR4 7TP

Mr Richard Brough Tameside General HospitalFountain Street, Ashton-Under-Lyne OL6 9RW

Mr P J O'Boyle Taunton and Somerset HospitalMusgrove Park, Taunton, Somerset TA1 5DA

Mr Ruaraidh P Macdonagh Taunton and Somerset Hospital

Musgrove Park, Taunton, Somerset TA1 5DA

Mr Mark J Speakman Taunton and Somerset Hospital

Musgrove Park, Taunton, Somerset TA1 5DA

Dr John Violet The Great Western HospitalMarlborough Road, Swindon, Wilts SN3 6BB

Mr Amir H Mostafid The Hampshire ClinicBasing Road, Old Basing, Basingstoke RG24 7AL

Professor Roger S Kirby The Prostate Centre 32 Wimpole Street, London W1G 8GTMr Magdi M Kirollos Torbay Hospital Lawes Bridge, Torquay, Devon TQ2 7AADr Anna Lydon Torbay Hospital Lawes Bridge, Torquay, Devon TQ2 7AAMr James P A MacDermott Torbay Hospital Lawes Bridge, Torquay, Devon TQ2 7AAMr Robert Mason Torbay Hospital Lawes Bridge, Torquay, Devon TQ2 7AADr Dawn M Carnell University College Hospital Mortimer Street, London W1T 3AAMr Mark Emberton University College Hospital Mortimer Street, London W1T 3AADr Stephen J Harland University College Hospital Mortimer Street, London W1T 3AAMr E O'Donoghue University College Hospital Mortimer Street, London W1T 3AA

Dr Heather Payne University College Hospital Mortimer Street, London W1T 3AA

Dr Gill M Duchesne

University College Hospital (Now at The Peter MacAllum Cancer Centre,, Melbourne, Australia) Mortimer Street, London W1N 3AA

Mr A R E BlacklockUniversity Hospital of Coventry and Warwickshire

Clifford Bridge Road, Walsgrave, Coventry CV2 2DX

Mr Ken M DesaiUniversity Hospital of Coventry and Warwickshire


Dr Robert GrieveUniversity Hospital of Coventry and Warwickshire


Dr Caroline HumberUniversity Hospital of Coventry and Warwickshire


Mr Rajagopalan Sriram

University Hospital of Coventry and Warwickshire


Dr Andrew Stockdale

University Hospital of Coventry and Warwickshire


Mr Michael WillisUniversity Hospital of Coventry and Warwickshire


Dr Jane WorldingUniversity Hospital of Coventry and Warwickshire


Mrs Karen Bailey University Hospital of Wales Heath Park, Cardiff, WalesCF14 4XW

Dr Alexandra Murray University Hospital of Wales Heath Park, Cardiff, WalesCF14 4XW

Mr Shibendra Datta University Hospital of Wales Heath Park, Cardiff, WalesCF14 4XW

Mr Owen Hughes University Hospital of Wales Heath Park, Cardiff, WalesCF14 4XW

Professor H Kynaston University Hospital of Wales Heath Park, Cardiff, Wales

CF14 4XW

Mr Philip N Matthews University Hospital of Wales Heath Park, Cardiff, Wales

CF14 4XW

Dr Jim Barber Velindre Hospital Whitchurch, Cardiff, Wales CF14 2TLDr Jason Lester Velindre Hospital Whitchurch, Cardiff, Wales CF14 2TLProfessor M D Mason Velindre Hospital Whitchurch, Cardiff, Wales CF14 2TLDr Kathryn Rowley Velindre Hospital Whitchurch, Cardiff, Wales CF14 2TLDr Owen Tilsley Velindre Hospital Whitchurch, Cardiff, Wales CF14 2TL

Mr Mark LongmuirW Scotland Regional Genetics Service

Yorkhill NHS Trust, Yorkhill, Glasgow G3 8SJ

Mr Lee Q Robinson Warrington Hospital Lovely Lane, Warrington WA5 1QG

Dr David A Jones Warwick Hospital Lakin Road, Warwick, Warks CV34 5BW

Mr D Christopher Lewis Warwick Hospital Lakin Road, Warwick, Warks

CV34 5BW

Mr John R Strachan Warwick Hospital Lakin Road, Warwick, Warks CV34 5BW

Mr John C Crisp Watford General HospitalVicarage Road, Watford, Hertfordshire WD1 8HB

Mr S Mitchell Watford General HospitalVicarage Road, Watford, Hertfordshire

WD18 0HB

Dr Elizabeth Sherwin West Suffolk Hospital Hardwick Lane, Bury St IP33 2QZ

EdmundsDr Duncan McLaren Western General Hosptial Crewe Road, Edinburgh EH4 2UXDr J W Taylor Western General Hosptial Crewe Road, Edinburgh EH4 2UXMr David N Tulloch Western General Hosptial Crewe Road, Edinburgh EH4 2UX

Dr C Ferguson Weston Park HospitalWhitham Road, Sheffield, South Yorkshire S10 2SJ

Dr Peter Kirkbride Weston Park HospitalWhitham Road, Sheffield, South Yorkshire S10 2SJ

Mr Richard Brown Wexham Park HospitalWexham street, Slough, Berkshire SL2 4HL

Mr O Karim Wexham Park HospitalWexham street, Slough, Berkshire SL2 4HL

Mr Marc Laniado Wexham Park HospitalWexham street, Slough, Berkshire SL2 4HL

Mr T PhilpWhipps Cross University Hospital

Whipps Cross Road, Leytonstone, London E11 1NR

Dr Paula WellsWhipps Cross University Hospital

Whipps Cross Road, Leytonstone, London E11 1NR

Mr Ralph Beard Worthing HospitalLyndhurst Road, Worthing, West Sussex

BN11 2DH

Mr Thomas Liston Worthing HospitalLyndhurst Road, Worthing, West Sussex

BN11 2DH

Mr Simon Woodhams Worthing Hospital

Lyndhurst Road, Worthing, West Sussex

BN11 2DH

Mr Alan R De Bolla Wrexham Maelor Hospital Croesnewydd Road, Wrexham LL13 7TD

Mr J P Kelleher Wycombe General HospitalQueen Alexander Rd, High Wycombe, Buckinghamshire HP11 2TT

Dr Andrew Weaver Wycombe General HospitalQueen Alexander Rd, High Wycombe, Buckinghamshire HP11 2TT

Mr Christopher H Parker Yeovil District Hospital

Higher Kingston, Yeovil, Somerset BA21 4AT

Mr Tim Porter Yeovil District HospitalHigher Kingston, Yeovil, Somerset BA21 4AT

Mr M J Stower York District HospitalWiggington Road, York, Yorkshire

YO31 8HE

Mr J R Wilson York District HospitalWiggington Road, York, Yorkshire

YO31 8HE

Mr Ernest K N Ahiaku Ysbyty Gwynedd Penrhosgarnedd, Bangor LL57 2PW

ACKNOWLEDGEMENTS

This work was supported by Cancer Research UK Grants C5047/A7357, C1287/A10118,

C5047/A3354, C5047/A10692, C16913/A6135, and C16913/A6835. We would also like to

thank the following for funding support: The Institute of Cancer Research and The

Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research

Campaign UK, The Orchid Cancer Appeal, The National Cancer Research Network UK,

The National Cancer Research Institute (NCRI) UK. We acknowledge NHS funding to the

NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal

Marsden NHS Foundation Trust. We also acknowledge grant support from The National

Health and Medical Research Council, Australia (209057, 251533, 450104, 390130),

VicHealth, The Cancer Council Victoria, The Prostate Cancer Foundation of Australia,

Cancer Council Queensland, The Whitten Foundation, and Tattersall’s. EAO, DMK, and

EMK acknowledge the Intramural Program of the National Human Genome Research

Institute for their support. The ProtecT study is ongoing and is funded by the Health

Technology Assessment Programme (projects 96/20/06, 96/20/99). The ProtecT trial and

its linked ProMPT and CAP (Comparison Arm for ProtecT) studies are supported by

Department of Health, England; Cancer Research UK grant number C522/A8649, Medical

Research Council of England grant number G0500966, ID 75466 and The NCRI, UK. The

epidemiological data for ProtecT were generated though funding from the Southwest

National Health Service Research and Development. DNA extraction in ProtecT was

supported by USA Dept of Defense award W81XWH-04-1-0280, Yorkshire Cancer

Research and Cancer Research UK. The authors would like to acknowledge the

tremendous contribution of all members of the ProtecT study research group. We should

like to acknowledge the NCRN nurses and Consultants for their work in the UKGPCS

study. The bio-repository from ProtecT is supported by the NCRI (ProMPT) study and the

Cambridge BMRC grant from NIHR.

The PROGRESS genotyping was supported by grants CA56678, CA92579, and CA97186

from the National Cancer Institute, National Institutes of Health, with additional support

from the Fred Hutchinson Cancer Research Center and the Intramural Program of the

National Human Genome Research Institute of NIH.

Ongoing work in Montreal has been funded in turn by the US Department of Defense (US

Army Grant DAMD17-00-1-0033; PI: W.D. Foulkes), the Canadian Genetic Diseases

Network and the National Institute of Health. Kimberly Kotar is thanked for recruitment of

the Montreal cases. The study in Switzerland was supported by the US Army Grant

DAMD17-00-1-0033 (PI: W.D. F.) and a grant from the Institut Central des Hôpitaux

Valaisans, Sion, Switzerland. We thank Joëlle Vuignier, Corinne Sierro, Barbara Varone

and Aurélie Ayme for technical and administrative assistance.

The Mayo group was supported by the US National Cancer Institute (R01CA72818).

The USC study was supported by the US National Cancer Institute (R01CA84979) and by

the California Cancer Research Program (99-00524V-10258).

The San Francisco study was supported by the California Cancer Research Fund (99-

00527V-10182).

The Tampere (Finland) study was supported by the Academy of Finland Grant 118413,

The Finnish Cancer Organisations, Sigrid Juselius Foundation, Reino Lahtikari Foundation

and The Medical Research Fund of Tampere University Hospital. The PSA screening

samples were collected by the the Finnish part of ERSPC ( European Study of Screening for Prostate Cancer). Linda Enroth is thanked for technical assistance.

The HaPCS was supported by an intramural Hannelore-Munke stipend to A.M. Jörn

Hagemann is thanked for his help in patient recruitment.

The FHCRC, Mayo, MCCS, Montreal, Tampere, UKGPCS, and Ulm groups are part of the

ICPCG supported by the NIH Grant No. U01 CA089600-04.

The Utah Population Database (UPDB) receives partial support for all datasets within it

from The University of Utah Huntsman Cancer Institute. Research in Utah was supported

by the Utah Cancer Registry, which is funded by contract N01-PC-35141 from the National

Cancer Institute's SEER program with additional support from the Utah State Department

of Health and The University of Utah. Some research support was provided by the

University of Utah General Clinical Research Center, Grant # M01 RR00064.

The Multiethnic Cohort Study was supported by National Cancer Institute (NCI) grants

CA63464 and CA54281.

The Moffitt group was supported by the US National Cancer Institute (R01CA128813, PI:

J.Y. Park).

http://www.erspc.org/

http://www.erspc.org/

Ongoing research work of CHSH is funded by the National Natural Science Foundation of

China (30671793).

The TASPRAC study was supported by the Cancer Council Tasmania, the Mazda

Foundation, Tasmanian Community Fund, Max Bruce Trust, Royal Hobart Hospital

Research Foundation, Perpetual Charitable Trusts, the Australian Cancer Research Fund

and the Tasmanian community. We would particularly like to thank the participants of the

TasPac and TasCaP studies, members of the TasPac and TasCap research teams, the

Tasmanian Cancer Registry, and the Tasmanian clinicians who have collaborated in this

study.

The Queensland Study would like to thank the staff at the Australian Red Cross Blood

Services for their assistance with the collection of risk factor information and blood

samples of healthy donor controls, staff at the Cancer Council Queensland for ProsCan

participant information, and members of the QUT Prostate Cancer Program and the QIMR

Molecular Cancer Epidemiology Laboratory for their assistance with recruitment and

biospecimen processing and members of the QIMR Cancer Genetics Laboratory for

technical advice.

The Penn Study is also known as the Study of Clinical Outcomes, Risk, and Ethnicity

(SCORE) at the University of Pennsylvania and was supported by NIH Grants R01-

CA08574 and P50-CA105641 as well as a grant from the Commonwealth of Pennsylvania

(PI: T. Rebbeck). The authors thank Charnita Zeigler-Johnson, Elaine Spangler, Margerie

Coomes, Stephen Gallagher, Amy Walker, and Klara Stefflova.

The Flint Men’s Health Study was supported by NCI SPORE in Prostate Cancer P50

CA69568, the Department of Defense Prostate Cancer Research Program Grant

DAMD17-03-0270, and the University of Michigan Comprehensive Cancer Center.

D. Easton is a Principal Research Fellow of Cancer Research UK. John Hopper is an

Australia Fellow of the NHMRC. A. Spurdle is an NHMRC Senior Research Fellow, J.

Dickinson is a Cancer Council Tasmania Fellow, J. Clements is an NHMRC Principal

Research Fellow, and J. Batra is supported by an IHBI postdoctoral fellowship.

We are grateful to the staff at Illumina and Tepnel Life Sciences for their help with this

study. We would like to acknowledge the help of Nathan Gauge, Charlotte Bamber for

sample collection and retrieval. The authors would like to acknowledge the tremendous

contribution of all members of the ProtecT study research group, especially those listed

and also Athene Lane and Michael Davies. The views and opinions expressed therein are

those of the authors and do not necessarily reflect those of the Department of Health of

England.

We should like to thank all the patients and control men who took part in this study.

SUPPLEMENTARY TEXT: DESCRIPTION OF THE ...europepmc.org/articles/PMC2846760/bin/NIHMS180501... ·...

Documents

Transcript of SUPPLEMENTARY TEXT: DESCRIPTION OF THE ...europepmc.org/articles/PMC2846760/bin/NIHMS180501... ·...